Our rapid liquid chromatography-mass spectrometry (rLC-MS) technology innovation and high throughput approaches have removed bioanalytical constraints to map dynamic, non-genetic biomarkers at speed, scale, and in a time- and cost-effective manner.
With more metabolite, lipid, and protein measures made in every sample, you can go beyond the genome to identify novel biomarkers that can inform and accelerate your studies for:
From discovery to preclinical and clinical phases, across disease areas and drug modalities.
From early disease detection to understanding the mechanisms underlying disease risk and progression.
Leverage our ultra-high throughput discovery infrastructure to extend beyond a genetic-centric to a multi-omic understanding of disease.
Fundamentally, Sapient’s proprietary rLC-MS allows us to take a biological sample like blood and, in that sample, capture and measure thousands of dynamic biomarkers.
We use these systems for nontargeted multi-omics analyses, including discovery metabolomics and lipidomics to profile broad, complex chemistries in a single run, as well as for discovery proteomics to significantly scale the number of proteins and proteoforms that can be measured in plasma, cells, and tissue.
This enables broader discovery to capture the most biologically relevant biomarkers, including yet-unknown molecules.
small molecule biomarkers measured in nontargeted method
proteins and post-translational modifications (PTMs) captured in cells and tissues
samples can be analyzed per day with these systems
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
